Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 2,754 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Norovirus Infections
Interventions: Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose, Placebo; Drug
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Long Beach, California • Lenexa, Kansas • Saint Paul, Minnesota

Conditions: Irritation Potential of Topic Agent
Interventions: ATx201 Gel 2%, ATx201 Gel 4%, Positive Control, Negative Control, ATx201 Placebo; Drug
Lead sponsor: UNION therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Arthroscopic Surgical Procedures, Anterior Cruciate Ligament Reconstruction
Interventions: Activated Incrediwear Products, Sham Incrediwear Products; Other
Lead sponsor: Oklahoma Joint Reconstruction Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Highly Active Antiretroviral Therapy (HAART); Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 46
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more

Conditions: Acne Vulgaris
Interventions: Vehicle, TSN2898; Drug
Lead sponsor: Thesan Pharmaceuticals, Inc.; Industry
Eligibility: 16 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: San Diego, California • Miami, Florida • High Point, North Carolina + 1 more

Conditions: COVID-19
Interventions: Aerobic Exercise Training, Education; Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Opioid Use Disorder
Interventions: [11C]-PHNO, Calcitriol, Placebo Control, PET Scan; Drug · Dietary Supplement · Other + 1 more
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Depression, Back Pain
Interventions: Higher-dose venlafaxine, Supportive management, Problem Solving Therapy for Depression and Pain; Drug · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Lighting Intervention Therapy, Sham LIT; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 50 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Physical Fitness
Interventions: The First Twenty, Comparison; Behavioral
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Stroke, High Intensity Interval Exercise
Interventions: Single, acute bout of high intensity interval exercise; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hypertension
Interventions: Artificial Intelligence (AI) Activity, 10,000 steps; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: AADC Deficiency
Interventions: AAV2-hAADC; Drug
Lead sponsor: Krzysztof Bankiewicz; Other
Eligibility: 24 Months and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2037
U.S. locations: 3
States / cities: San Francisco, California • Columbus, Ohio

Conditions: Healthy
Interventions: Empagliflozin/Metformin XR FDC, 25 mg Empagliflozin/1000 mg Metformin XR, FDC, 1 tablet Empagliflozin/2 tablets Metformin XR, 1 tablet Empagliflozin/3 tablets Metformin XR; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypertension
Interventions: Technology-enabled Team Care, Enhanced Usual Care; Other
Lead sponsor: East Carolina University; Other
Eligibility: 19 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Greenville, North Carolina • Wilmington, North Carolina

Conditions: Acute Lymphoblastic Leukemia
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 807 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Metabolism, Physical Fitness
Interventions: High Intensity Interval Training, Moderate Intensity Training; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 17 Years to 22 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Glioblastoma WHO Grade IV
Interventions: Quisinostat; Drug
Lead sponsor: Nader Sanai; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Fibrous Dysplasia/McCune-Albright Syndrome
Interventions: MRI-based Neuroimaging, Non-contrast MRI, 18F-FDG-PET/CT, 18F-NaF-PET/CT; Diagnostic Test
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 45 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Diseases, Natriuretic Peptides, Cardiometabolic Diseases, Energy Expenditure, Glucose Metabolism, Exercise, Obesity
Interventions: Study diet, Exercise capacity VO2 max determination, Exercise Challenge, Glucose Challenge; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Stress Disorders, Post-Traumatic
Interventions: Transcranial Magnetic Stimulation, Robotic Arm; Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Antoio, Texas

Conditions: Glaucoma
Interventions: AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 18
States / cities: Inglewood, California • Petaluma, California • Poway, California + 15 more

Conditions: Primary Progressive Aphasia, Apraxia of Speech
Interventions: high-definition transcranial direct current stimulation (HD-tDCS); Device
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Squamous Cell Carcinoma, Nonmelanoma Skin Cancer, Cutaneous Squamous Cell Carcinoma
Interventions: sentinel lymph node biopsy (SLNB); Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

Incrediwear ACL MCL Arthroscopic Surgery Recovery Study

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)

Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System

ADAPT: Addressing Depression and Pain Together

7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD

The First 20 Fire Academy Recruits Exercise Training Program

Blood Flow Response and Acute INterval Exercise

AI Activity Study in Patients With Elevated Blood Pressure

A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Heart to Heart: BP Control Partners

Motor Proficiency And Physical Activity in Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

High Intensity Interval Versus Continuous Moderate Intensity Training: Maximizing the Benefits of Exercise in Overweight Adolescents

Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

Pain in Fibrous Dysplasia

GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study

Accelerated Image-Guided Robotically Delivered Transcranial Magnetic Stimulation for Combat PTSD

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck